Working… Menu

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) (REMINET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02288377
Recruitment Status : Recruiting
First Posted : November 11, 2014
Last Update Posted : June 13, 2018
Information provided by (Responsible Party):
Federation Francophone de Cancerologie Digestive